Atlas Trials

A Study of Linperlisib (YY-20394) in Combination With Rituximab in Patients With Relapsed/Refractory Indolent NHL

Clinical trial NCT06981988 · NOT_YET_RECRUITING

Trial details

NCT number
NCT06981988
Sponsor
Jiangsu HengRui Medicine Co., Ltd.
Status
NOT_YET_RECRUITING
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Relapsed/Refractory Indolent NHL
Start date
2025-06-01
Primary completion
2025-08-01
Enrollment
80

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.